VERVE-201 / Eli Lilly, Verve Therapeutics - LARVOL DELTA

Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels. (PubMed, Expert Opin Ther Targets) - "These observations rapidly catalyzed the development of pharmacologic strategies to inhibit ANGPTL3 using monoclonal antibodies (e.g. evinacumab), antisense oligonucleotides (e.g. vupanorsen), small interfering ribonucleic acid (e.g. zodasiran and solbinsiran), and most recently genome-editing approaches (e.g. VERVE-201 and CTX310). The degree of hypertriglyceridemia in the patient's baseline lipid profile appears to be an important determinant of drug response. Drawing on genetic, mechanistic, and clinical trial data, the promise and limitations of ANGPTL3 inhibition are considered and its potential place in future lipid-lowering strategies is outlined."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • ANGPTL3

VT-20101: Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia (clinicaltrialsregister.eu) - P1 | N=10 | Not yet recruiting | Sponsor: Verve Therapeutics Inc.

New P1 trial • Dyslipidemia

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Verve Therapeutics, Inc. | Trial completion date: Mar 2027 ➔ Dec 2027 | Trial primary completion date: Mar 2027 ➔ Dec 2027

Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) - "Initial Data for the Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 Expected in the Second Quarter of 2025....Dosing has been completed or is ongoing in participants across the first three dose cohorts, 0.3 mg/kg, 0.45 mg/kg, and 0.6 mg/kg, in the Heart-2 clinical trial....Verve expects to report the final data for the dose escalation portion of the Heart-2 clinical trial and initiate the Phase 2 clinical trial for the PCSK9 program in the second half of 2025. Verve plans to deliver the opt-in data package for the PCSK9 program and receive a decision from Eli Lilly and Company (Lilly) in the second half of 2025....ANGPTL3 Program: Pulse-1 Phase 1b Clinical Trial for VERVE-201 Continues to Progress....Verve expects to provide an update on the ANGPTL3 program in the second half of 2025."

P1 data • Cardiovascular • Heterozygous Familial Hypercholesterolemia

Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Verve Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • Metabolic Disorders

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Verve Therapeutics, Inc.

New P1 trial • Dyslipidemia • Metabolic Disorders